---
title: "Satellos Bioscience releases Phase 2 TRAILHEAD interim data update presentation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292076998.md"
description: "Satellos Bioscience released interim Phase 2 TRAILHEAD data for SAT-3247 in Duchenne muscular dystrophy. In four adults, MRI showed a 3.7% average reduction in biceps fat fraction by month 5, and wearable-measured total effort increased ~34% by month 6. Upper-extremity strength remained stable. No serious adverse events or discontinuations occurred, with 100% compliance over a mean exposure of 186 days."
datetime: "2026-07-08T13:34:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292076998.md)
  - [en](https://longbridge.com/en/news/292076998.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292076998.md)
---

# Satellos Bioscience releases Phase 2 TRAILHEAD interim data update presentation

-   Satellos Bioscience published an interim six-month update from its Phase 2 TRAILHEAD study of SAT-3247 in adults with Duchenne muscular dystrophy. \* Study readout covered four adults aged 21-28; mean drug exposure 186 days; 100% compliance. \* No serious treatment-emergent adverse events; no withdrawals or discontinuations tied to adverse events. \* MRI biceps fat fraction fell 3.7% on average by month 5; declines reported in all four participants. \* Wearable-measured total effort rose about 34% by month 6; upper-extremity strength measures held stable. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [MSLE.US](https://longbridge.com/en/quote/MSLE.US.md)

## Related News & Research

- [Capricor publishes advisory committee presentation on deramiocel clinical data in Duchenne muscular dystrophy](https://longbridge.com/en/news/293953736.md)
- [Minoryx’s NEZGLYAL wins positive CHMP opinion for pediatric cerebral adrenoleukodystrophy in EU](https://longbridge.com/en/news/293903277.md)
- [Secretome Therapeutics Expands Rare Disease Leadership Team](https://longbridge.com/en/news/293965029.md)
- [Imricor Launches US Operations with Cardiac Imaging System at Rady Children’s Hospital in San Diego](https://longbridge.com/en/news/293860801.md)
- [Mount Ridley Mines Issues 24 Million Unquoted Performance Rights Under Incentive Plan](https://longbridge.com/en/news/293586188.md)